Prevalence of life-threatening conditions in children

Virginia Randall1, Jason Cervenka, David Arday

  • 1Department of Pediatrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA. vrandall@usuhs.mil

Insights

The prevalence of life-threatening conditions (LTC) in military children is 0.15%, with 3,976 cases identified. This finding aids in planning for pediatric healthcare within the military health system.

Area of Science:

  • Pediatric Health
  • Healthcare Systems Research
  • Epidemiology

Background:

  • Military health systems serve a unique pediatric population.
  • Accurate prevalence data is crucial for resource allocation and program planning.
  • Life-threatening conditions (LTC) in children require specialized care and support.

Purpose of the Study:

  • To estimate the prevalence of children with life-threatening conditions (LTC) within the military health system (MHS).
  • To inform program planning and resource allocation for pediatric care in the MHS.
  • To respond to a Congressional inquiry regarding pediatric LTC prevalence.

Main Methods:

  • Developed a case definition for LTC using the "death trajectory" concept.
  • Conducted an unduplicated count of children with LTC in the MHS database (FY 2001/2002) using ICD-9 codes.
  • Reviewed literature for prevalence data using similar case definitions.

Main Results:

  • Identified 3,976 children with LTC in a population of 2.6 million children.
  • Calculated a prevalence of 0.15% for pediatric LTC within the MHS.
  • Prevalence aligns with findings in other single-payer healthcare systems.

Conclusions:

  • The prevalence of pediatric LTC in the MHS is 0.15%.
  • This methodology is applicable to other healthcare systems with searchable ICD-9 databases.
  • Findings support the need for targeted pediatric healthcare services within the MHS.
Abstract

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...